Ariad (ARIA) Shares Plunge 10+% as Results of Phase 2 Study of Ponatinib Show Serious Side Effects
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Join SI Premium – FREE
Shares of Ariad Pharma (Nasdaq: ARIA) are crumbling in early-morning trade Monday. After opening about flat, the stock is now down 10 percent for the session. Downside intensified sharply just after 10:30am ET.
An abstract from the American Society of Hematology was released earlier demonstrating serious side effects in 17 percent of chronic myeloid leukemia patients using the experimental ponatinib. About 15 percent of patients stopped therapy with the drug.
An abstract from the American Society of Hematology was released earlier demonstrating serious side effects in 17 percent of chronic myeloid leukemia patients using the experimental ponatinib. About 15 percent of patients stopped therapy with the drug.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Alzamend Neuro fMRI data accepted for neuroscience conference poster
- Blue Star Gold reports phase 2 drilling results at Nutaaq target
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
